Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review.

ABSTRACT: Neuroendocrine tumor (NET) incidence has grown. The treatment landscape for advanced NETs is rapidly evolving, but there are limited head-to-head data to guide treatment sequencing decisions. We assessed the available clinical data to aid practicing clinicians in their routine clinical decision-making. Clinical trials have demonstrated efficacy benefits for new therapies in advanced NETs. Emerging long-term data from these trials have enabled clinicians to make more accurate risk-benefit assessments, particularly for patients receiving multiple lines of therapy. However, clinical data specifically regarding treatment sequencing are limited. In lieu of definitive data, treatment sequencing should be based on disease-related factors (e.g., site of tumor origin, volume of disease) and patient

SUBMITTER: Chauhan A 

PROVIDER: S-EPMC9656186 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature